Modification on ursodeoxycholic acid (UDCA) scaffold. Discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1)

Journal of Medicinal Chemistry

Volumn 57, Issue 18, 2014, Pages 7687-7701

  Sepe, Valentina ^a   Renga, Barbara ^b   Festa, Carmen ^a   Damore, Claudio ^b   Masullo, Dario ^a   Cipriani, Sabrina ^b   Di Leva, Francesco Saverio ^a   Monti, Maria Chiara ^c   Novellino, Ettore ^a   Limongelli, Vittorio ^a   Zampella, Angela ^a   Fiorucci, Stefano ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Nuova Facoltà di Medicina   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CELL PROTEIN; CELL SURFACE G PROTEIN COUPLED BILE ACID RECEPTOR 1; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; G PROTEIN COUPLED RECEPTOR; GPBAR1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTASIS; CONTROLLED STUDY; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; SMALL INTESTINE; AGONISTS; ANALOGS AND DERIVATIVES; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; ENZYME SPECIFICITY; HEK293 CELL LINE; HEPG2 CELL LINE; PROTEIN CONFORMATION;

DRUG DISCOVERY; HEK293 CELLS; HEP G2 CELLS; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; SUBSTRATE SPECIFICITY; URSODEOXYCHOLIC ACID;

EID: 84907572503     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500889f     Document Type: Article

References (42)

1. Makishima, M.; Okamoto, A. Y.; Repa, J. J.; Tu, H.; Learned, R. M.; Luk, A.; Hull, M. V.; Lustig, K. D.; Mangelsdorf, D. J.; Shan, B. Identification of a nuclear receptor for bile acids Science 1999, 284, 1362-1365
2. Parks, D. J.; Blanchard, S. G.; Bledsoe, R. K.; Chandra, G.; Consler, T. G.; Kliewer, S. A.; Stimmel, J. B.; Willson, T. M.; Zavacki, A. M.; Moore, D. D.; Lehmann, J. M. Bile acids: natural ligands for an orphan nuclear receptor Science 1999, 284, 1365-1368
3. Baes, M.; Gulick, T.; Choi, H. S.; Martinoli, M. G.; Simha, D.; Moore, D. D. A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements Mol. Cell. Biol. 1994, 14, 1544-1552
4. Makishima, M.; Lu, T. T.; Xie, W.; Whitfield, G. K.; Domoto, H.; Evans, R. M.; Haussler, M. R.; Mangelsdorf, D. J. Vitamin D receptor as an intestinal bile acid sensor Science 2002, 296, 1313-1316
5. Choi, H. S.; Chung, M.; Tzameli, I.; Simha, D.; Lee, Y. K.; Seol, W.; Moore, D. D. Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR J. Biol. Chem. 1997, 272, 23565-23571
6. Wang, Y. D.; Chen, W. D.; Moore, D. D.; Huang, W. FXR: a metabolic regulator and cell protector Cell Res. 2008, 18, 1087-1095
7. Zhang, Y.; Lee, F. Y.; Barrera, G.; Lee, H.; Vales, C.; Gonzalez, F. J.; Willson, T. M.; Edwards, P. A. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 1006-1011
8. Renga, B.; Mencarelli, A.; DAmore, C.; Cipriani, S.; Baldelli, F.; Zampella, A.; Distrutti, E.; Fiorucci, S. Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition FASEB J. 2012, 26, 3021-3031
9. Wang, Y. D.; Chen, W. D.; Wang, M.; Yu, D.; Forman, B. M.; Huang, W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response Hepatology 2008, 48, 1632-1643
10. Fiorucci, S.; Rizzo, G.; Antonelli, E.; Renga, B.; Mencarelli, A.; Riccardi, L.; Orlandi, S.; Pruzanski, M.; Morelli, A.; Pellicciari, R. A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis J. Pharmacol. Exp. Ther. 2005, 314, 584-595
11. Baptissart, M.; Vega, A.; Maqdasy, S.; Caira, F.; Baron, S.; Lobaccaro, J. M.; Volle, D. H. Bile acids: from digestion to cancers Biochimie 2013, 95, 504-517
12. Watanabe, M.; Houten, S. M.; Mataki, C.; Christoffolete, M. A.; Kim, B. W.; Sato, H.; Messaddeq, N.; Harney, J. W.; Ezaki, O.; Kodama, T.; Schoonjans, K.; Bianco, A. C.; Auwerx, J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation Nature 2006, 439, 484-489
13. Thomas, C.; Gioiello, A.; Noriega, L.; Strehle, A.; Oury, J.; Rizzo, G.; Macchiarulo, A.; Yamamoto, H.; Mataki, C.; Pruzanski, M.; Pellicciari, R.; Auwerx, J.; Schoonjans, K. TGR5-mediated bile acid sensing controls glucose homeostasis Cell. Metab. 2009, 10, 167-177
14. Fiorucci, S.; Mencarelli, A.; Palladino, G.; Cipriani, S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders Trends Pharmacol. Sci. 2009, 30, 570-580
15. Fiorucci, S.; Cipriani, S.; Baldelli, F.; Mencarelli, A. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders Prog. Lipid Res. 2010, 49, 171-185
16. Tiwari, A.; Maiti, P. TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders Drug Discovery Today 2009, 14, 523-530
17. Schaap, F. G.; Trauner, M.; Jansen, P. L. Bile acid receptors as targets for drug development Nature Rev. Gastroenterol. Hepatol. 2014, 1, 55-67
18. Azzaroli, F.; Mehal, W.; Soroka, C. J.; Wang, L.; Lee, J.; Crispe, N.; Boyer, J. L. Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes Hepatology 2002, 36, 49-54
19. Keene, C. D.; Rodrigues, C. M.; Eich, T.; Chhabra, M. S.; Steer, C. J.; Low, W. C. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntingtons disease Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 10671-10676
20. Alberts, D. S.; Martinez, M. E.; Hess, L. M.; Einspahr, J. G.; Green, S. B.; Bhattacharyya, A. K.; Guillen, J.; Krutzsch, M.; Batta, A. K.; Salen, G.; Fales, L.; Koonce, K.; Parish, D.; Clouser, M.; Roe, D.; Lance, P. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence J. Natl. Cancer Inst. 2005, 97, 846-853
21. Mi, L.-Z.; Devarakonda, S.; Harp, J. M.; Han, Q.; Pellicciari, R.; Willson, T. M.; Khorasanizadeh, S.; Rastinejad, F. Structural basis for bile acid binding and activation of the nuclear receptor FXR Mol. Cell 2003, 11, 1093-1100
22. DAmore, C.; Di Leva, F. S.; Sepe, V.; Renga, B.; Del Gaudio, C.; DAuria, M. V.; Zampella, A.; Fiorucci, S.; Limongelli, V. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors J. Med. Chem. 2014, 57, 937-954
23. Pellicciari, R.; Sato, H.; Gioiello, A.; Costantino, G.; Macchiarulo, A.; Sadeghpour, B. M.; Giorgi, G.; Schoonjans, K.; Auwerx, J. Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5 J. Med. Chem. 2007, 50, 4265-4268
24. Pellicciari, R.; Costantino, G.; Camaioni, E.; Sadeghpour, B. M.; Entrena, A.; Willson, T. M.; Fiorucci, S.; Clerici, C.; Gioiello, A. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid J. Med. Chem. 2004, 47, 4559-4569
25. Sepe, V.; Ummarino, R.; DAuria, M. V.; Renga, B.; Fiorucci, S.; Zampella, A. The first total synthesis of solomonsterol B, a marine pregnane X receptor agonist Eur. J. Org. Chem. 2012, 5187-5194
26. Schteingart, C. D.; Hofmann, A. F. Synthesis of 24-nor-5 beta-cholan-23-oic acid derivatives: a convenient and efficient one-carbon degradation of the side chain of natural bile acids J. Lipid. Res. 1988, 29, 1387-1395
27. Tserng, K. Y.; Klein, P. D. Formylated bile acids: improved synthesis, properties, and partial deformylation Steroids 1977, 29, 635-648
28. Sepe, V.; Ummarino, R.; DAuria, M. V.; Lauro, G.; Bifulco, G.; DAmore, C.; Renga, B.; Fiorucci, S.; Zampella, A. Modification in the side chain of solomonsterol A: discovery of cholestan disulfate as a potent pregnane-X-receptor agonist Org. Biomol. Chem. 2012, 10, 6350-6362
29. Iguchia, Y.; Kihira, K.; Nishimaki-Mogami, T.; Une, M. Structure-activity relationship of bile alcohols as human farnesoid X receptor agonist Steroids 2010, 75, 95-100
30. Macchiarulo, A.; Gioiello, A.; Thomas, C.; Pols, T. W. H.; Nuti, R.; Ferrari, C.; Giacche, N.; De Franco, F.; Pruzanski, M.; Auwerx, J.; Schoonjans, K.; Pellicciari, R. Probing the binding site of bile acids in TGR5 ACS Med. Chem. Lett. 2013, 4, 1158-1162
31. Fujino, T.; Une, M.; Imanaka, T.; Inoue, K.; Nishimaki-Mogami, T. Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation J. Lipid Res. 2004, 45, 132-138
32. Renga, B.; Migliorati, M.; Mencarelli, A.; Cipriani, S.; DAmore, C.; Distrutti, E.; Fiorucci, S. Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter Biochim. Biophys. Acta 2011, 1809, 157-165
33. Fiorucci, S.; Baldelli, F. Farnesoid X receptor agonists in biliary tract disease Curr. Opin. Gastroenterol. 2009, 25, 252-259
34. Mencarelli, A.; Renga, B.; DAmore, C.; Santorelli, C.; Graziosi, L.; Bruno, A.; Monti, M. C.; Distrutti, E.; Cipriani, S.; Donini, A.; Fiorucci, S. Dissociation of intestinal and hepatic activities of FXR and LXRa supports metabolic effects of terminal ileum interposition in rodents Diabetes 2013, 62, 3384-3393
35. Bobeldijk, I.; Hekman, M.; de Vries-van derWeij, J.; Couliera, L.; Ramakera, R. Quantitative profiling of bile acids in biofluids and tissues based on accurate mass high resolution LC-FT-MS: compound class targeting in a metabolomics workflow J. Chromatogr., B 2008, 871, 306-313
36. Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. A semiempirical free energy force field with charge-based desolvation J. Comput. Chem. 2007, 28, 1145-1152
37. Maestro, version 9.3; Schrodinger, LLC: New York, 2012.
38. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids J. Am. Chem. Soc. 1996, 118, 11225-11236
39. MacroModel, version 9.9; Schrodinger, LLC: New York, 2012.
40. LigPrep, version 2.5; Schrodinger, LLC: New York, 2012.
41. Epik, version 2.3; Schrodinger, LLC: New York, 2012.
42. Di Leva, F. S.; Festa, C.; DAmore, C.; De Marino, S.; Renga, B.; DAuria, M. V.; Novellino, E.; Limongelli, V.; Zampella, A.; Fiorucci, S. Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands J. Med. Chem. 2013, 56, 4701-4717